Document is current

Article History

Received: 17 February 2025

Accepted: 12 April 2025

First Online: 27 May 2025

Declarations

:

: Katia Mancuso has received honoraria from Celgene, Takeda, Amgen, Sanofi and Janssen; Lucia Pantani has received honoraria from GlaxoSmithKline, Pfizer and Sanofi; Paola Tacchetti has received honoraria from Amgen, Bristol-Myers Squibb/Celgene, Janssen, Takeda, AbbVie, Sanofi, GlaxoSmithKline and Pfizer; Michele Cavo has received honoraria and has served in a consulting/advisory role for Amgen, AbbVie, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Menarini-Stemline, Sanofi, and Karyopharm Therapeutics; Elena Zamagni has received honoraria and has served in advisory role for Janssen, Bristol-Myers Squibb, Sanofi, Amgen, GlaxoSmithKline, Pfizer, Oncopeptides, Menarini-Stemline; Ilaria Rizzello has received honoraria from Amgen, GlaxoSmithKline and Sanofi and advisory role for GlaxoSmithKline. Flavia Bigi, Mauro Fiacchini, Roberta Restuccia, Simone Masci, Gaia Mazzocchetti, Marco Talarico, Michele Puppi, Ilaria Sacchetti, Enrica Manzato, Miriam Iezza, Chiara Sartor, Rania Abd Alatif, Erica Pastore, and Simona Barbato declare no potential conflicts of interest.

: The study was approved by CE AVEC and conducted in accordance with the International Conference on Harmonization Guidelines on Good Clinical Practice and the principles of the Declaration of Helsinki. All participants signed an informed consent form prior to their inclusion in the study.